Moderna's vaccine testing produces COVID-19 antibodies in all 45 participants
- 4 years ago
미 바이오기업 모더나 "코로나19 백신 임상시험서 항체 형성"
U.S. biotech company Moderna says there have been some promising early results from its first human tests for a potential vaccine for COVID-19.
It said the vaccine produced virus-fighting antibodies in all 45 participants that were similar or greater than those in patients who had recovered from the virus.
The vaccine also produced neutralizing antibodies in at least eight participants, which is considered important in acquiring protection.
Approved by the FDA last month, Moderna will proceed with the second phase of testing involving 600 people.
U.S. biotech company Moderna says there have been some promising early results from its first human tests for a potential vaccine for COVID-19.
It said the vaccine produced virus-fighting antibodies in all 45 participants that were similar or greater than those in patients who had recovered from the virus.
The vaccine also produced neutralizing antibodies in at least eight participants, which is considered important in acquiring protection.
Approved by the FDA last month, Moderna will proceed with the second phase of testing involving 600 people.